Bactiguard recruits experienced Chief Medical and Technology Officer
Stefan Grass with extensive clinical experience as a physician and researcher, combined with senior positions in the pharmaceutical industry, has been recruited to a newly established, global role as Chief Medical and Technology Officer. He will assume his position in October 2019 and report to the CEO.
“As a physician and researcher specialized in anaesthesia and intensive care, Stefan Grass has extensive experience of the product portfolio Bactiguard offers and the complications healthcare associated infections lead to, both for patients and healthcare providers. He is genuinely development-oriented and after a number of intensive years in healthcare chose to take a role as Head of Medical Affairs in the pharmaceutical industry.
The combination of clinical, research-related and commercial experience makes him ideal for the new role in Bactiguard's management team and it is with pleasure that I welcome him on board,” says Christian Kinch, CEO.
Stefan Grass holds a medical degree from the Karolinska Institute and is specialized in anaesthesia and intensive care. He has a PhD in neurophysiology, with focus on pain from the Karolinska University Hospital and has been active at the cardiothoracic department, among others.
Since 2011, Stefan Grass has been a member of the Nordic management team at CSL Behring, with responsibility for Medical Affairs and Market Access.
Stefan Grass is 47 years old and will take up his position in mid-October, with responsibility for Bactiguard's global clinical activities. He will also be involved in the development and marketing of the company's product portfolio for infection prevention and new licensing opportunities in various therapy areas.
In his role as Chief Medical and Technology Officer, Stefan Grass will report to the CEO and be part of Bactiguard’s Executive Management team.
For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 72 226 23 28
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com
Tags:
